1-(N,N-diphenylcarbamoyl)-4-(N,N-di-n-pentylcarbamoyl)piperazine-2-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(N,N-diphenylcarbamoyl)-4-(N,N-di-n-pentylcarbamoyl)piperazine-2-carboxylic acid
• 英文别名: 4-(dipentylcarbamoyl)-1-(diphenylcarbamoyl)piperazine-2-carboxylic acid
• 化学式: C₂₉H₄₀N₄O₄
• 分子量: 508.661
• InChiKey: OCZZSQRGBFEJLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  84.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 1-(N,N-diphenylcarbamoyl)-4-(N,N-di-n-pentylcarbamoyl)piperazine-2-carboxylic acid 以 乙醚 为溶剂， 生成 methyl 1-(N,N-diphenylcarbamoyl)-4-(N,N-di-n-pentylcarbamoyl)piperazine-2-carboxylate
  参考文献：
  名称：

  N,N-diacylpiperazines

  摘要：

  一般结构为##STR1##的二酰基哌嗪类化合物包括：选择性针对II型（AT.sub.2）亚型的血管紧张素II（A-II）拮抗剂，用于治疗脑血管、认知和中枢神经系统疾病；用于治疗炎症性疾病、疼痛或偏头痛的嗜肽受体拮抗剂；以及用于治疗心血管疾病如心绞痛、高血压或缺血的钙通道阻滞剂。

  公开号：

  US05292726A1

文献信息

• N,N-diacylpiperazine tachykinin antagonists
  申请人：Merck & Co., Inc.

  公开号：US05344830A1

  公开（公告）日：1994-09-06

  Diacylpiperazines of general structure ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

  通用结构式为##STR1##的二酰基哌嗪是一种治疗炎症性疾病、疼痛或偏头痛、哮喘的缓激肽受体拮抗剂，以及治疗心血管疾病如心绞痛、高血压或缺血的钙通道阻滞剂。
• METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：EP1996183A1

  公开（公告）日：2008-12-03
• METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN
  申请人：Smith Maree Therese

  公开号：US20100292159A1

  公开（公告）日：2010-11-18

  This invention discloses the use of angiotensin II receptor 2 (AT 2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals and particularly in human subjects. The AT 2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory conditions.
• Method of Treatment or Prophylaxis of Inflammatory Pain
  申请人：Spinifex Pharmaceuticals Pty Ltd

  公开号：US20140142116A1

  公开（公告）日：2014-05-22

  A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (AT 2 receptor) antagonists is disclosed. The AT 2 receptor antagonist may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory pain.
• METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN
  申请人：Novartis AG

  公开号：US20160052925A1

  公开（公告）日：2016-02-25

  A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (AT 2 receptor) antagonists is disclosed. The AT 2 receptor antagonist may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory pain.